Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,915 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1791
- Phase 1/Phase 2478
- Phase 3344
- Phase 4125
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia280
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts102
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,915 total
- NCT06737523RecruitingPhase 1
A new combination therapy for relapsed or refractory AML
This trial tests a three-drug combination for patients whose AML has returned or not responded to prior treatment. It aims to see if adding a new drug (Chiglitazar) to standard treatments (Venetoclax and Azacitidine) can help control the leukemia.
Xiamen, FujianAges 18 years+ - NCT06788639Recruiting
Long-term study of Breyanzi for CLL/SLL in real-world care
This study looks at people with CLL or SLL who have already been treated with the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) in routine medical care. It collects information about how well the treatment works and how patients are doing over time, without giving any new treatment.
Milwaukee, WisconsinAges 18 years+ - NCT06794268Recruiting
Long-term health study for people with lymphoma treated with liso-cel
This study looks at patients with a type of lymphoma (follicular lymphoma) who have already received a CAR T-cell therapy called liso-cel. Researchers want to track their health over time and see how well the treatment works and how safe it is in routine medical care.
Milwaukee, WisconsinAges 18 years+ - NCT04271644RecruitingPhase 1/Phase 2
CAR-T treatment targeting BCMA for hard-to-treat myeloma
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
Kunming, YunnanAges 18–75 - NCT04776330RecruitingPhase 1/Phase 2
BCMA-targeted CAR-T for relapsed or refractory multiple myeloma
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
Kunming, YunnanAges 18–75 - NCT05127980Recruiting
Study of immune antibodies after first-time EBV infection
This study looks at how the immune system’s antibodies behave after a first-time EBV infection, including whether they mistakenly react with the body’s own tissues. You might be offered a chance to help doctors understand why some people get longer or more intense symptoms from infectious mononucleosis.
BaselAges 18 years+ - NCT06299462RecruitingPhase 1/Phase 2
Preventing GVHD with PTCy and ATG in stem cell transplant
This trial tests a combination of two drugs (PTCy and ATG) to prevent graft-versus-host disease after a stem cell transplant from a matched donor. It is for adults with certain blood cancers who are between 18 and 60 and have a suitable donor.
Rio de Janeiro, Rio de JaneiroAges 18–60 - NCT06743945RecruitingPhase 2
Study of polatuzumab, rituximab, CHP for transformed DLBCL
This trial tests a combination of drugs (POLA-R-CHP) as a first treatment for patients whose large B-cell lymphoma has changed from a slower-growing type. It aims to see if this therapy is effective and safe for newly diagnosed patients.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06835140RecruitingPhase 1
NK cell immunotherapy for AML that has stopped responding to treatment
This trial tests a new type of immunotherapy using special immune cells (NK cells) that target the CD123 marker found on AML cells. It may help people whose AML has not responded to standard treatments and who have a healthy donor available.
Beijing, ChinaAges 18–70 - NCT07369024RecruitingPhase 2
Study of low-dose ketamine for sickle cell pain crisis
This study tests whether a low-dose of ketamine (a pain medicine) can help children and young adults with sickle cell disease who are in a pain crisis. It aims to provide better pain relief while avoiding some side effects of standard painkillers.
Torrance, CaliforniaAges 5–20 - NCT07366801RecruitingPhase 2/Phase 3
Preventing graft versus host disease in children with blood cancer
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
MoscowAges 1–25 - NCT07365306RecruitingPhase 2
Epcoritamab with chemo before stem cell transplant for DLBCL
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Duarte, CaliforniaAges 18 years+ - NCT07362199RecruitingPhase 2
New combo treatment for chronic ITP
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07362407Enrolling by invitation
Cannabinoid treatment study for patients in Brazil
This study tracks how cannabis-based medicines work in real life. It looks at how people feel and function while using these treatments prescribed by their doctor.
Florianópolis, Santa CatarinaAges 18 years+ - NCT07362966RecruitingPhase 4
Colchicine for heart health after a heart attack
This study tests whether a low-dose medicine called colchicine can reduce inflammation and slow down artery blockages in people who have a specific gene change (TET2) and have recently had a heart attack. The goal is to see if it helps prevent future heart problems.
Shenyang, LiaoningAges 40–85 - NCT07362095RecruitingPhase 1/Phase 2
Luspatercept for anemia after a stem cell transplant
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
Guangzhou, GuangdongAges 18–70 - NCT07362238RecruitingPhase 2
Daratumumab vs Rituximab for pediatric ITP
This study compares daratumumab to rituximab for children with primary immune thrombocytopenia (ITP) that hasn't improved with steroids. The goal is to find a better treatment to raise platelet counts and reduce bleeding risk.
TianjinAges 6–18 - NCT07370103Recruiting
Predicting low blood pressure in liver disease patients after anesthesia
This study uses an ultrasound to measure blood flow in the neck's main artery to see if it can predict a dangerous drop in blood pressure after you are put to sleep for surgery. It is for adult patients with chronic liver disease who are having planned surgery.
CairoAges 18 years+ - NCT07362225Recruiting
MPN Progress Registry: Tracking Symptoms and Progression
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
Chicago, IllinoisAges 18 years+ - NCT07362810RecruitingPhase 2
Adding IL-11 to G-CSF for faster blood cell recovery after transplant
This trial tests whether adding a second drug (IL-11) to the standard G-CSF can help your blood cells recover faster after a stem cell transplant using your own cells. It is for people with multiple myeloma or lymphoma who are about to have this transplant.
Zhengzhou, HenanAges 18–70 - NCT07366502Recruiting
Liposomal vs Regular Oral Iron After Sleeve Gastrectomy
This trial compares two types of oral iron supplements for people who have iron deficiency anemia after a sleeve gastrectomy. It aims to find which type is more effective at raising iron levels.
Istanbul, kadıköyAges 18–65 - NCT07365007Recruiting
Diet study to improve nerve pain after chemo
This study tests a diet program delivered online to help reduce nerve damage symptoms like numbness and tingling caused by chemotherapy. It is for cancer survivors who completed treatment and still have these symptoms.
Ann Arbor, MichiganAges 18 years+ - NCT07368270RecruitingPhase 1
Anti-PD1 armored CAR-T cells for adults with relapsed/refractory DLBCL
This trial tests a new kind of cell therapy that combines CAR-T cells (which find and kill cancer cells) with an anti-PD1 'armor' to boost their power. It is for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to earlier treatments.
SuzhouAges 18 years+ - NCT07369895RecruitingPhase 1
A new cell therapy for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (O&D-001) for multiple myeloma that has returned or not responded to previous treatments. It targets specific markers on myeloma cells (BCMA or GPRC5D) and aims to shrink the cancer.
Guangzhou, GuangdongAges 18–75
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,915 recruiting hematology studies from the U.S. registry right now, out of 7,288 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.